Kallyope

At Kallyope, we are leveraging unique insights into neural signaling pathways and developing innovative medicines for the treatment of migraine and metabolic disorders. Our late-stage pipeline focuses on delivering effective, easy to use, and well-tolerated agents based on novel neural circuits. Kallyope was founded by world-leading neuroscientists whose groundbreaking research into previously unexplored neural networks is now being carried forward by a team of experienced drug developers. Based in New York City, our accomplished scientists and drug developers bring together agile innovation and real-world focus to create major value for patients. Our pipeline is enabled by the Klarity™ Platform, including our lead migraine candidate moving into pivotal studies for the acute treatment of migraine, and our novel metabolism programs based on a novel feeding circuit set to enter clinical studies in mid-2026.